SIS
OVID icon

Sound Income Strategies’s Ovid Therapeutics OVID Stock Holding History

Sound Income Strategies’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6
Closed -$13 – 1798
2026
Q1 		$13 Hold
6
– – ﹤0.01% 2569
2025
Q4 		$9 Hold
6
– – ﹤0.01% 2504
2025
Q3 		$10 Hold
6
– – ﹤0.01% 1682
2025
Q2 		$2 Hold
6
– – ﹤0.01% 1605
2025
Q1 		$2 Hold
6
– – ﹤0.01% 1554
2024
Q4 		$6 Hold
6
– – ﹤0.01% 1461
2024
Q3 		$7 Hold
6
– – ﹤0.01% 1394
2024
Q2 		$5 Hold
6
– – ﹤0.01% 1367
2024
Q1 		$18 Buy
+6
New +$20 ﹤0.01% 1332

Other funds holding OVID

PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
SFG
Sovereign Financial Group Stamford, Connecticut $654M AUM 32.34% 1-Year Est. Return
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
TCWM
Total Clarity Wealth Management St. Charles, Illinois $515M AUM 27.37% 1-Year Est. Return
BMC
Benin Management Corp Wilton, Connecticut $494M AUM 25.95% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
TFM
TFC Financial Management Boston, Massachusetts $902M AUM 21.74% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Sound Income Strategies's OVID Position: Q2 2026 in Review

Sound Income Strategies sold out of Ovid Therapeutics (OVID) in Q2 2026, closing a stake of 6 shares — an estimated $13 sold.

Sound Income Strategies first reported a position in OVID in Q1 2024 and held it in 9 quarters. The position peaked at $18 in Q1 2024. 10 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Sound Income Strategies reported no remaining Ovid Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Sound Income Strategies sold 6 Ovid Therapeutics shares in Q2 2026, an estimated $13.
  • Sound Income Strategies first reported a position in Ovid Therapeutics in Q1 2024 and held it in 9 quarters.
  • Sound Income Strategies's Ovid Therapeutics position peaked at $18 in Q1 2024.
  • 10 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Sound Income Strategies's 13F filing for Q2 2026, filed 20 Jul 2026.